Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel Detection in NSCLC Treated With TC Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 \~75 years~* Pathology: Confirmed by pathology (histology or cytology) for advanced non-small cell lung cancer~* Have indications of paclitaxel/carboplatin chemotherapy, suitable for paclitaxel chemotherapy (independent of clinical tumor stage or chemotherapy type or palliative chemotherapy lines)~* At least one measurable tumor lesions (according to RECIST 1.1 criteria)~* ECOG PS score: 0 to 2 points~* Life expectancy: more than 3 months~* Bone marrow reserve function is good, the function of organs (liver and kidney) is good, can satisfy the conditions of implementation chemotherapy. neutrophil count ≥1.5×109/l, platelet ≥75×109/l, hemoglobin \>9g/dl, Total Bilirubin ≤1.5×ULN\*, transaminase \<2.5×ULN\*, creatinine ≤1.5×ULN\*,or creatinine clearance rate ≥45ml/min. ULR: Upper Limit Of Normal.~* Sign the informed consent form; Compliance is good, can be followed up, willing to comply with the requirements of the study~Exclusion Criteria:~* ECOG Performance Scores \> 2 points~* Organic disease (heart, liver, kidney disease etc), Active infection Organ transplantation immunosuppressive therapy, not capable to complete 4 - 6 cycles of paclitaxel / carboplatin chemotherapy.~* Any other tumor history not cured in 3 years before this trial.~* Bone marrow function or organs function not eligible for chemotherapy.~* Diabetic patients currently receiving the standard anti- diabetes treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel and Carboplatin regimen (Type: EXPERIMENTAL): Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection. 21 days per cycle; 6 cycles in total.

Based on this trial design, predict the completion outcome and termination type (if applicable).